Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Breast 1

Conditions

KRAS Mutant Non-Small Cell Lung Cancer 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × mirdametinib × Other solid neoplasm × Clear all
NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
60 enrolled
Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡